Corcept Therapeutics Announces Second Quarter Results and Corporate Update
August 07, 2012 08:30 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Aug 7, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces Underwritten Public Offering of Common Stock
July 02, 2012 09:21 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Jul 2, 2012) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization...
Corcept Therapeutics Commences Public Offering of Common Stock
July 02, 2012 07:24 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Jul 2, 2012) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and...
Corcept Therapeutics Announces First Quarter Results and Corporate and Development Update
May 03, 2012 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - May 3, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces National Product Launch of Korlym(TM) for Patients With Endogenous Cushing's Syndrome
April 10, 2012 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Apr 10, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that Korlym™ (mifepristone) 300 mg Tablets is available by prescription...
UPDATE: Data Published in Premier Endocrinology Journal Shows Korlym(TM) Provides Significant Clinical Improvement in Patients With Endogenous Cushing's Syndrome
April 09, 2012 12:45 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Apr 9, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharamceutical company engaged in the discovery, development and commercialization of drugs for the...
Data Published in Premier Endocrinology Journal Shows Korlym(TM) Provides Significant Clinical Improvement in Patients With Endogenous Cushing's Syndrome
April 09, 2012 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Apr 9, 2012) - The results of Corcept Therapeutics Incorporated's phase 3 SEISMIC trial published in The Journal of Clinical Endocrinology and Metabolism (JCEM)...
Corcept Therapeutics Announces Exercise of Warrants and Private Placement of New Warrants
March 26, 2012 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Mar 26, 2012) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of...
Korlym(TM) (mifepristone), the First Approved Medication for Patients With Endogenous Cushing's Syndrome, to Be Available by April 11
March 22, 2012 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Mar 22, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that it would be ready to ship Korlym to patients by April 11th, three weeks ahead of...
Corcept Therapeutics Announces Fourth Quarter Results and Corporate and Development Update
March 05, 2012 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Mar 5, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...